Besremi (Ropeginterferon

Medical Uses: Besremi (ropeginterferon alfa-2b-njft) is an interferon alfa-2b used for the treatment of adults with polycythemia vera (a rare, chronic and life-threatening disorder caused by a defective hematopoietic stem cell in the bone marrow, which results in a chronic increase of red blood cells, white blood cells, and platelets). 

Recommended Dosage: 

Patients Not Already on Hydroxyurea: The recommended starting dosage of Besremi for patients not on hydroxyurea is 100 mcg administered by subcutaneous (SC) injection every 2 weeks. Increase the dose of this medicine by 50 mcg every 2 weeks (up to a maximum of 500 mcg), until the hematological parameters are stabilized (hematocrit less than 45%, platelets less than 400 x 109 /L, and leukocytes less than 10 x 109 /L).

Patients Transitioning from Hydroxyurea: When transitioning to Besremi from hydroxyurea, start treatment at 50 mcg by subcutaneous (SC) injection every 2 weeks along with hydroxyurea. Gradually taper off the hydroxyurea by reducing the total biweekly dose by 20 to 40% every 2 weeks during Weeks 3 to 12. Increase the dose by 50 mcg every 2 weeks (up to a maximum of 500 mcg) until the hematological parameters are stabilized (hematocrit less than 45%, platelets less than 400 x 109 /L, and leukocytes less than 10 x 109 /L). Discontinue hydroxyurea by Week 13. 

• Ropeginterferon alfa-2b-njft 500 mcg/mL may be responsible for causing or worsening depression. In some instances, it can cause suicidal thoughts or behavior. Patients with a known history of mental health complications should be closely monitored. If depressive symptoms emerge, immediate psychiatric attention is recommended.
• This medicine may impact hormone-secreting organs, like the thyroid and pancreas. It could lead to hypothyroidism or hyperthyroidism. During treatment, particularly with clients having known endocrine disorders, regular blood checks to monitor hormones may be required.
• This medication may cause cardiac problems such as hypertension, chest pain, or arrhythmia. Patients with a history of heart disease need to be monitored very closely. If you experience any chest pain, nausea, or shortness of breath, report it to your physician right away.
• Ropeginterferon alfa-2b-njft is likely to cause decreased white blood cells, red blood cells, and platelets. This could heighten susceptibility to infections, anemia, or bleeding. There is a need for regular blood tests to monitor blood counts and make further treatment decisions.
• Some patients may experience allergies such as a rash, swelling, itching, or breathing difficulties. Though rare, severe hypersensitivity requires urgent treatment. Allergic symptoms should be treated immediately, and consult a physician as soon as required.
• This medication has been associated with cases of acute pancreatitis. Associated symptoms may be excruciating abdominal pain and nausea. Such symptoms may require treatment interruption or discontinuation of therapy, however, this decision is solely based on the physician’s recommendation.
• Ropeginterferon alfa-2b-njft may also induce colitis, which will manifest as abdominal pain, diarrhea, and blood per rectum. These symptoms, while they may be reassuring, require intervention by a medical professional to assess the situation. The condition may require some form of supportive care or alteration to existing treatment.
• There may be some severe complications involving the lungs, such as lung inflammation and scarring. Under these circumstances, the patients may begin to demonstrate a persistent cough with difficulty in breathing or tightness in the chest. If any of these symptoms are noted, imaging studies as well as clinical workup will be necessary, and the therapy should be adjusted accordingly.
• This medicine can affect vision. This may lead to blurred sight or eye pain. Eye exams are very important before and during treatment. Any sudden vision changes should be reported to a healthcare provider (HCP) immediately to prevent life-threatening complications.
• Monitoring the patients’ blood cholesterol and triglyceride levels is important. Cardiovascular long-term effects may raise concern if the elevated lipid levels remain unaddressed. Adjustments to dietary plans or medication may be necessary to mitigate the risk of these adverse outcomes.
• Damage to the liver, such as with an increase in liver enzymes or hepatitis, is possible during treatment. Symptoms may be jaundice, increased pigmentation of the skin, and exhaustion. There should be regular assessment of liver tests; if abnormalities are found, then modification of the dose may be necessary.

What documents are required to import BESREMi to India?

BESREMi (ropeginterferon alfa-2b-njft) injections can be imported by patients or government hospitals in the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

Is BESREMi available in India?

BESREMi (ropeginterferon alfa-2b-njft injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Besremi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

BESREMi can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of BESREMi (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Besremi 500 mcg/mL injection price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source BESREMi (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Besremi®?

Ropeginterferon alfa-2b-njft is a Generic Name for the trade name drug Besremi®.

What is the Manufacturer’s Name of Besremi®?

Besremi® is manufactured by PharmaEssentia Corporation.

Is Besremi approved by the FDA?

Yes, Besremi® is approved by the FDA. Date of first approval: November 12, 2021.

What is the dosage and form of Besremi® supplied?

Besremi is supplied in injection: 500 mcg/mL solution in a single-dose prefilled syringe for subcutaneous (SC) use.

What are the most common side effects of Besremi® 500 mcg/mL injections? 

The most common side effect of Besremi® injection are influenza-like illness, fatigue, arthralgia, pruritus, musculoskeletal pain, and nasopharyngitis.

How much does Besremi® 500 mcg/mL injection cost in India?

Prices of Besremi injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Besremi 500 mcg/mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Besremi® 500 mcg/mL injections be available in SAARC countries? 

Apart from Gulf countries, Besremi® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Besremi® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Besremi® 500 mcg/mL injections online in India?

Yes, one can buy Besremi 500 mcg/mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Besremi® injections through legal channels. 

What are the storage conditions of Besremi® 500 mcg/mL injections?

Store this therapeutic drug in a refrigerator at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect from light. Never freeze it.